Difference in distribution between alpha-synuclein oligomers and Lewy bodies in Parkinson’s disease brain
Objective: To examine the distribution of alpha-synuclein (αSYN) oligomers in Parkinson’s disease (PD) brains and compare the distribution of αSYN oligomers and Lewy bodies. Background:…Fear of progression in Parkinson’s disease: Preliminary results of a pilot cross-sectional study
Objective: To examine the prevalence of fear of progression (FoP) in Parkinson's disease (PD) patients, and to analyze which sociodemographic, clinical and neuropsychological factors are…Clinical Features of Depressive Disorders in Parkinson’s Disease: Possibilities of their Correction
Objective: Nowadays Parkinson's disease is one the problems of medicine which is waiting its solution. Background: The aim of our study was to examine the…Effects of multimodal balance training supported by rhythmical auditory stimuli in people with advanced stages of Parkinson’s disease: A randomized clinical trial
Objective: To study the effectiveness of balance training with and without rhythmical auditory cues in people with advanced stages of PD (H&Y4). Background: Non-pharmacological interventions…A video self-modelling virtual reality intervention for freezing of gait in Parkinson’s disease: Preliminary findings from a pilot trial
Objective: To determine the feasibility and acceptability of video self-modelling using a virtual reality headset plus physical practice for managing freezing of gait (FOG) in…Quantifying movement to measure Parkinson’s Disease severity and progression in a Phase 2 Study (SPARK)
Objective: To develop and evaluate objective measures of Parkinson’s disease (PD) severity and progression by applying dynamical systems analysis to inertial sensor kinematic data. Background:…Ampreloxetine (TD-9855), a long-acting, norepinephrine reuptake inhibitor (NRI) for the treatment of neurogenic orthostatic hypotension (nOH) in subjects with synucleinopathies: Phase 3 clinical program
Objective: To confirm: 1) clinical efficacy and safety of once-daily oral ampreloxetine in a 4-week double-blind (DB), placebo-controlled (PC) study (NCT03750552); 2) durability of efficacy…Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease
Objective: Prove safety and feasibility of delivering allogeneic bone marrow-derived mesenchymal stem cells (MSC) intravenously in escalated doses to patients with idiopathic Parkinson’s disease (PD).…A Discrete-Choice Experiment Evaluating Preferences for On-Demand Treatments for Patients with Parkinson’s Disease and “OFF” Episodes
Objective: To quantify patient preferences for on-demand treatments among patients with Parkinson’s disease (PD) and “OFF” episodes. Background: Patients with PD develop potentially disabling “OFF”…Efficacy of opicapone in different levodopa-containing treatment regimens in Parkinson’s disease patients with motor fluctuations
Objective: To evaluate the efficacy of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations being treated with different levodopa-containing treatment regimens. Background: OPC,…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 149
- Next Page »